NHSBT Research and Development
Welcome to NHSBT Research and Development
The success of NHSBT's strategy to achieve long-term improvements in patient outcomes requires an innovative research programme. The effective
application of novel technologies, processes and products drives the advancement of clinical practice, but this can only be accomplished by
having an integrated R&D programme which supports organisational priorities. This requirement to undertake or commission R&D is within our statutory
Our R&D Programme is unique – within the public, private and academic sectors there are no other organisations capable of delivering
an R&D programme that spans all our products and services. This is due to the combination of our partnerships with top class
universities, our clearly defined operational objectives and our expertise in translation into new products, services and clinical guidelines.
Our world-leading R&D programme underpins our business strategies and guides international transfusion and transplantation practice.
The 2015 – 2020 R&D Strategy sets out innovative plans in support of Blood 2020, Taking Organ Transplantation to 2020 and our operating
strategies in Diagnostic and Therapeutic Services.
Call for applications for a clinical trial in acquired coagulopathy
NHSBT funds clinical trials and studies of blood components and alternative strategies in patients who may need transfusion support.
We now invite calls in the area of acquired coagulopathy in any clinical setting where replacement therapy is currently given.
Studies to test novel diagnostic markers are also welcome. The indicative budget is £200,000 per year for up to 4 years.
Applications for prelimary/pilot studies are acceptable.
There will be a two-stage application process.
Preliminary application forms
must be submitted to
by 5.00 pm on Friday 26th August 2016.
Shortlisted applicants will be invited to submit a full proposal which will be peer reviewed, with final decisions in Spring 2017.
For further information please contact Dr Nick Watkins, Assistant Director, Research and Development at
Acquired Coagulopathy Call
Strategic Plan 2015-20
Triennial Report 2009-12